| Literature DB >> 21694987 |
A Semalty1, Mona Semalty, U Nautiyal.
Abstract
Enalapril maleate is used in the treatment of hypertension and angina pectoris. It shows low bioavailability due to high hepatic first pass metabolism. Hence the present work was undertaken to formulate mucoadhesive buccal films of enalapril maleate with an objective to improve therapeutic efficacy, patient compliance and the bioavailability. In the present study ten formulations of mucoadhesive drug delivery system of enalapril maleate were prepared as buccal films, by solvent casting technique. Sodium carboxymethylcellulose, hydroxylpropylmethylcellulose, hydroxyethylcellulose and polyvinyl pyrrolidone K-90 were used as mucoadhesive polymers. Prepared films were evaluated for their weight, thickness, surface pH, swelling index, drug content uniformity, in vitro residence time, folding endurance in vitro release and permeation studies. Films exhibited controlled release over more than 10 h in permeation studies. It was concluded that the films containing 20 mg of enalapril maleate in sodium carboxymethylcellulose 2% w/v and hydroxyethyl cellulose 2% w/v (formulation F5), showed good swelling, a convenient residence time and promising controlled drug release, thus can be selected for the development of buccal film for effective therapeutic uses.Entities:
Keywords: Buccal film; enalapril; ex vivo studies; in vitro studies; mucoadhesive
Year: 2010 PMID: 21694987 PMCID: PMC3116300 DOI: 10.4103/0250-474X.78522
Source DB: PubMed Journal: Indian J Pharm Sci ISSN: 0250-474X Impact factor: 0.975
PHYSICAL EVALUATION OF MUCOADHESIVE BUCCAL FILMS OF ENALAPRIL MALEATE
PHYSICAL EVALUATION OF MUCOADHESIVE BUCCAL FILMS OF ENALAPRIL MALEATE
Fig. 1Cumulative percent drug release of fi lms in pH 6.6 phosphate buffer
Formulations F1 (—♦—), F2 (—●—), F3 (—*—), F4 (—×—), F5 (—■—), F6(—▲—) F7 (—+—), F8 (—○—), F9 (—◊—) and F10 (—□—)]
Fig. 2Ex vivo permeation studies of selected mucoadhesive buccal films of enalapril
Permeation studies in pH 7.4 phosphate buffer of formulations F5 (—■—) containing SCMC 2% w/v and HEC 2% w/v and F6 (—▲—) containing PVP K-90 5 % w/v and SCMC 2 % w/v with 20 mg enalapril in each film.